Coinbase founder Brian Armstrong’s longevity tech company, NewLimit, has raised $435 million in a Series C round, valuing the company at $3.1 billion. It is developing drugs based on Yamanaka factor technology to reverse cellular aging, with its first drug targeting alcohol-related liver disease set to enter clinical trials, aiming to extend healthspan and intervene in aging. https://t.co/8EGsS0NMjC
火星财经Share
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.